U.S. pharma hits out at Gilead decision

January 20, 2015 12:12 am | Updated April 20, 2016 04:57 am IST - Washington

The decision to deny U.S. biotechnology firm Gilead Sciences a patent for its anti-Hepatitis C drug sofosbuvir shows that India continues to have a “deteriorating climate for innovation,” according to a leading trade group here.

Mark Grayson, a spokesman for PhRMA, which represents the pharmaceutical research and biopharmaceutical companies, said to The Hindu that if India wanted to attract foreign investment “It needs to have a policy that recognises the importance of innovation.”

PhRMA’s comments come days after the Indian Patent Office rejected an application for sofosbuvir, and less than a week before U.S. President Barack Obama lands in New Delhi to join the country’s Republica Day celebrations as Chief Guest.

Although senior State Department officials including Assistant Secretary of State for Economic and Business Affairs Charles Rivkin have in recent days alluded to the need for bilateral alignment on Intellectual Property Rights (IPR) protections, Mr. Grayson said, “Right now it looks like nothing has changed even though Modi government has said they will be looking at IPR policy.”

However PhRMA continues to be “hopeful” that the Indian government will understand their perspective, Mr. Grayson added.

The U.S. private sector and government concerns over India’s “philosophical” differences on IPR issues has a long history and is likely to feature prominently in the summit discussions next week between Mr. Modi and Mr. Obama.

A variety of federal agencies here, including the U.S. Trade Representative and the U.S. International Trade Commission have argued that there are growing concerns with respect to the environment for IPR protection and enforcement in India.

Last year the USITC launched an investigation into whether India’s IPR policies, which denied patents to anti-cancer drugs such as Novartis’ Glivec and Bayer’s Nexavar while granting compulsory licenses to domestic producers of generic versions of certain drugs, “were harming the U.S. economy by discriminating against American firms.”

This week industry insiders criticised some reports in Indian media that compared India’s IPR decisions to the U.S. Food and Drug Administration’s crackdown on Indian generic drug manufacturers over quality control issues, saying “There is nothing further from the truth.”

Top News Today

Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.